Key facts
- It has raised $2.9M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Plug and Play Tech Center, MassChallenge, Venture Kick, Ecole Polytechnique Federale de Lausanne, Innosuisse — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Neurosoft Bioelectronics
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurosoft Bioelectronics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurosoft Bioelectronics
Developer of soft implantable electrodes intended to diagnose and treat neurological diseases by recording or electrically stimulating neural tissues. The company's technology develops compliant neural interfaces that can achieve long-term bio-integration in the body by conforming to the static and dynamic mechanics of neural tissue, enabling doctors to improve therapeutic outcomes in patients and open up new applications for neural interfaces.
- Sector
- Healthcare
- HQ
- Geneva, Switzerland
- Founded
- 2019
- Employees
- 19
- Website
- neurosoft-bio.com/
- Ownership
- Privately Held (backing)
Neurosoft Bioelectronics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurosoft Bioelectronics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurosoft Bioelectronics in its N-PORT filings yet. We sweep new filings monthly.